Use of erythropoiesis-stimulating agents (ESAs) dropped 31% in Medicare from 2007 to the end of 2011 as a result of changes in reimbursement and more conservative dosing recommendations from FDA, a Government Accountability Office report says.
GAO was directed by the Medicare Improvements for Patients and Providers Act of 2008 to report on trends in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?